METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise against fatty liver in Mid-Stage trial
Disease control OngoingThis study tests a new medicine called miricorilant in 175 adults with nonalcoholic steatohepatitis (NASH/MASH), a type of fatty liver disease that can lead to liver damage. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor their doc…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 17, 2026 11:18 UTC
-
New drug targets fatty liver in people with 'fat gene' variant
Disease control OngoingThis early-stage study tests a new medicine called LY3849891 in people with fatty liver disease (MASLD) who have a specific gene change (PNPLA3 I148M). The main goal is to check the drug's safety and how the body processes it. Researchers will also use blood tests and liver scans…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 17, 2026 11:09 UTC